Candriam SCA’s Express Scripts Holding Company ESRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-66,485
Closed -$6.32M 868
2018
Q3
$6.32M Sell
66,485
-7,077
-10% -$603K 0.08% 275
2018
Q2
$5.68M Sell
73,562
-128,510
-64% -$9.64M 0.09% 272
2018
Q1
$14M Sell
202,072
-81,434
-29% -$6.21M 0.24% 111
2017
Q4
$21.2M Buy
283,506
+21,729
+8% +$1.39M 0.37% 70
2017
Q3
$16.6M Buy
261,777
+10,418
+4% +$647K 0.29% 91
2017
Q2
$16M Sell
251,359
-2,494
-1% -$157K 0.3% 83
2017
Q1
$16.7M Buy
253,853
+53,806
+27% +$3.7M 0.32% 74
2016
Q4
$13.8M Sell
200,047
-7,725
-4% -$554K 0.32% 84
2016
Q3
$14.7M Sell
207,772
-13,479
-6% -$1.01M 0.35% 70
2016
Q2
$16.8M Buy
221,251
+3,399
+2% +$250K 0.44% 62
2016
Q1
$14.9M Sell
217,852
-105,327
-33% -$7.57M 0.37% 72
2015
Q4
$28.2M Buy
323,179
+117,349
+57% +$10.1M 0.76% 28
2015
Q3
$16.7M Buy
205,830
+56,545
+38% +$4.92M 0.41% 59
2015
Q2
$13.3M Buy
149,285
+60,729
+69% +$5.31M 0.28% 101
2015
Q1
$7.69M Sell
88,556
-95,979
-52% -$8.05M 0.15% 179
2014
Q4
$15.6M Buy
+184,535
New +$14.4M 0.33% 97

Other funds holding ESRX

Candriam SCA's ESRX Position: Q4 2018 in Review

Candriam SCA sold out of Express Scripts Holding Company (ESRX) in Q4 2018, closing a stake of 66,485 shares — an estimated $6.32M sold.

Candriam SCA first reported a position in ESRX in Q4 2014 and held it in 16 quarters. The position peaked at $28.2M in Q4 2015. 16 funds tracked by Wall St. Rank hold ESRX as of Q4 2018.

  • Candriam SCA reported no remaining Express Scripts Holding Company position as of Q4 2018 after selling out during the quarter.
  • Candriam SCA sold 66,485 Express Scripts Holding Company shares in Q4 2018, an estimated $6.32M.
  • Candriam SCA first reported a position in Express Scripts Holding Company in Q4 2014 and held it in 16 quarters.
  • Candriam SCA's Express Scripts Holding Company position peaked at $28.2M in Q4 2015.
  • 16 funds tracked by Wall St. Rank held Express Scripts Holding Company as of Q4 2018.

Based on Candriam SCA's 13F filing for Q4 2018, filed 14 Feb 2019.